Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New test could match ovarian cancer patients to the right drug

NCT ID NCT03877796

Knowledge-focused Sponsor: Allarity Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 5 times

Summary

This study is testing a device called a Drug Response Predictor (DRP) that uses a sample of a patient's tumor to see if it will respond to certain cancer drugs. The trial involves 60 people with advanced ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the DRP can guide future treatment choices and also check if it correctly predicts past drug responses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Drug Response Predictor (DRP) assay
What this could lead to
If successful, this could help doctors choose the right cancer drug for each patient, improving treatment effectiveness.
What could go wrong
This is an early-stage study with only 60 participants, and the predictor may not accurately forecast drug response in all cases.
Why investors are watching

Allarity Therapeutics is testing whether its DRP method can predict which ovarian cancer patients will respond to its investigational drugs by analyzing their archived tumor tissue. For a micro-cap company with few products, a successful validation of this companion diagnostic could make its drug pipeline more credible and targeted.

If it works: A positive result could show that DRP reliably identifies patients likely to benefit, which may strengthen Allarity's position in developing its drugs and attract partnership interest. It could also support future trial designs that enroll only predicted responders, making studies smaller and faster.

If it fails: The trial is small and observational, and the method may fail to predict responses accurately. If results are weak or the study is delayed, Allarity's drug development plans could lose credibility, and the company may face difficulty advancing its pipeline.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2019

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients will be identified at their already planned treatment and or at control visits at the oncology department

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with histological confirmed epithelia ovarian cancer * Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible. * Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting * FFPE tumor tissue available Exclusion Criteria: * Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy. * Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epithelial ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beatson West of Scotland Cancer Centre

    RECRUITING

    Glasgow, Scotland, G12 0YN, United Kingdom

  • Emory Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital

    RECRUITING

    London, United Kingdom

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

  • OU Health Stephenson Cancer Center

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

  • Swedish Center for Research and Innovation

    RECRUITING

    Seattle, Washington, 98122, United States

  • The Blavatnik Family-Chelsea Medical Center at Mount Sinai

    RECRUITING

    New York, New York, 10011, United States

  • University Medical Center Cancer Center

    RECRUITING

    Lubbock, Texas, 79415, United States

  • University of New Mexico Comprehensive Cancer

    RECRUITING

    Albuquerque, New Mexico, 87131, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.